BioSpace News Archive

Midatech Pharma PLC is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in recurrent glioblastoma will continue with a planned dose escalation following a positive recommendation from the study’s Data Safety Monitoring Board.

Nevro Corp. today announced a series of data presentations supporting the use of the company’s HFX™ 10 kHz Therapy for patients with chronic pain. Results will be presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting held from January 12-15, 2023.

Spectral Medical Inc. today provided a business update focusing on Tigris, the Company’s follow-on study designed to build on knowledge gained from the earlier EUPHRATES trial, which evaluated the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a virtual fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference.

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced the appointment of Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its board of directors.

Advaxis, Inc. today announced an update on the Phase 1 clinical study evaluating ADXS-504, the company’s off-the-shelf neoantigen drug candidate, in patients with biochemically recurrent (early) prostate cancer that is being conducted at Columbia University Irving Medical Center.

VolitionRx Limited announces the availability of its Nu.Q® Vet Cancer Test through the IDEXX Laboratories, Inc. reference laboratory network in the U.S.

Myomo, Inc. today announced the pricing of its “best efforts” public offering of 20,000,000 shares of common stock (or common stock equivalents in lieu thereof) at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.

Jupiter Neurosciences, Inc. today announced that it has appointed Saleem Elmasri, CPA, as new Chief Financial Officer, effective January 1, 2023.

CNS Pharmaceuticals, Inc today announced an investigator-initiated Phase 1b/2 trial evaluating the Company’s novel anthracycline, Berubicin, which will be conducted at the Pomeranian Medical University (PUM) in Szczecin, Poland.